<DOC>
	<DOC>NCT02139020</DOC>
	<brief_summary>The investigators will collect plasma samples at baseline, during treatment, and at progression.</brief_summary>
	<brief_title>Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients</brief_title>
	<detailed_description>In this study, the investigators will collect plasma samples at baseline, during treatment, and at progression. This plasma bank will be used to study the potential value of some biomarkers to predict treatment activity or resistance to cetuximab or other targeted agents</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>patients treated with radiation therapy and cetuximab according to Bonner et al patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. patients treated with a molecular targeted agent as a part of a clinical study patients with another type of head and neck cancer patients non treated with targeted therapies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Targeted therapies</keyword>
	<keyword>Plasma samples</keyword>
</DOC>